Antibiotics and Hydroxychloroquine in Crohn's

Study Purpose

There is growing evidence that Crohn's disease may be caused by replication of bacteria, perhaps particularly E. coli, within macrophages (a specialized sort of white blood cell). Laboratory studies show that a combination of antibiotics that can penetrate macrophages (such as ciprofloxacin and doxycycline) together with the anti-malarial drug hydroxychloroquine (which makes the contents of macrophage vesicles more alkaline and helps them to kill intracellular bacteria) is particularly effective at killing the E. coli within macrophages.

Recruitment Criteria

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Accepts Healthy Volunteers
No

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Study Type
Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patient is willing to participate in the study and has signed the informed consent - Patients aged 18 or over with Crohn's disease diagnosed by conventional clinical, radiological and histological criteria.
  • - Crohn's disease involving small bowel, colon or both.
  • - Active Crohn's disease: Crohn's Disease Activity Index (CDAI)> 220 and CRP>10mg/l.
  • - Patients receiving mesalazine (5ASA) must have had a stable dose for at least one month.
  • - Patients receiving Azathioprine, or Mercaptopurine (who will be separately stratified) must have had a stable dose for at least 3 months - Women of child bearing potential must have a negative urine pregnancy test prior to the start of study medication

    Exclusion Criteria:

    - Patients under 18 or unable to give informed consent.
  • - Any antibiotic use within the previous 4 weeks - Known sensitivity to Ciprofloxacin, Doxycycline, Hydroxychloroquine, or Budesonide - Patients with a history of tendon disorders related to Fluoroquinoline administration - Any change to immunosuppressive therapy (Azathioprine, or Mercaptopurine) within the previous 3 months.
  • - Use of Infliximab or Adalimumab (anti-TNF antibody) or methotrexate within the previous 3 months - Concurrent use of systemic corticosteroids in excess of oral prednisolone 5 mgs/day or budesonide 3mg/day) - Any change to medication for Crohn's disease in previous 4 weeks.
  • - Patients with complications requiring surgery (significant intestinal obstruction, perforation or abscess) - CDAI >450 - Participation in other trials in the last 3 months.
  • - Serious intercurrent infection or other clinically important active disease (including renal and hepatic disease) - Pregnant, post-partum (<3months) or breast feeding females - Patients with abnormal visual acuity (that does not correct with glasses) or unexplained visual symptoms - Women of Child Bearing Potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period (double barrier methods such as condoms or diaphragms with spermicidal gel or foam), and for up to 4 weeks after the study.
- Patients who need to continue to receive oral contraceptives (if unwilling to use double barrier methods), oral anticoagulants tricyclic antidepressants, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, Sucralfate, or Cyclosporine

Trial Details

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

Trial ID:
NCT01783106

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase
Phase 2

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Lead Sponsor
Royal Liverpool University Hospital

The person who is responsible for the scientific and technical direction of the entire clinical study.

Principal Investigator
N/A
Principal Investigator Affiliation N/A

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Agency Class
OtherOtherOther
Overall Status Recruiting
Countries United Kingdom

The disease, disorder, syndrome, illness, or injury that is being studied.

Conditions
Crohn's Disease
Additional Details

Trial Design This is an Open Label Active Study to Compare the Efficacy of 4 weeks Combination Antibiotic Therapy (Oral Ciprofloxacin 500mg bd plus Doxycycline 100mg bd and Hydroxychloroquine 200mg tds) followed by a further 20 weeks continued therapy with Doxycycline 100mg bd and Hydroxychloroquine 200mg tds with Standard Therapy (Oral Budesonide 9mg per day for 8 weeks followed by 6mg per day for 2 weeks and subsequent 3mg per day over a further 2 weeks) in the treatment of adults with Active Crohn's Disease. Patients who fail to respond by 10 weeks will be offered the opportunity to cross over onto the alternative treatment. Primary endpoint:

  • - Remission, defined as Crohn's Disease activity index (CDAI) <150 at 10 weeks without addition of any other medication or treatment for the Crohn's Disease.
  • - Remission, defined as CDAI ≤150 maintained through to 24 weeks - Remission, defined as CDAI ≤150 maintained through to 52 weeks Secondary Endpoints: - Remission defined as CDAI <150 at 4 weeks - Response defined as a fall in CDAI by >70 points at 4 weeks and 10 weeks - Markers of cost (days admitted to hospital, days unable to carry out normal daily activities, need for surgery) - Quality of life at 4 weeks, at 10 weeks, or Early Withdrawal - Patient global assessment of symptom severity by 10 cm visual analogue score at 4 weeks, at 10 weeks, or Early Withdrawal - Adverse Events and possible drug-related side effects: nausea, diarrhoea, mood disturbance, sleep disturbance - will all be assessed at each visit - Fall in Faecal Calprotectin 100 patients will be randomised in order to obtain evaluable population 50 patients per treatment arm.
6.1 Informed Consent It is the responsibility of the Investigator to obtain written Informed Consent from patients before any trial procedure is carried out. All consent documentation must be in accordance with applicable regulations and GCP. Each patient is requested to sign the Patient Informed Consent Form after the patient has received and read the written patient information and received an explanation of what the study involves, including but not limited to: the objectives, potential benefits and risk, inconveniences and the subject's rights and responsibilities. A copy of the informed consent documentation (Consent Form and Subject Information) [Appendix 1] must be given to the patient. A copy will be retained in the Source Documentation and the original in the Investigator Site File. Inclusion Criteria (i) Patient is willing to participate in the study and has signed the informed consent (ii) Patients aged 18 or over with Crohn's disease diagnosed by conventional clinical, radiological and histological criteria. (iii) Crohn's disease involving small bowel, colon or both. (iv) Active Crohn's disease: Crohn's Disease Activity Index (CDAI)> 220 and CRP>10mg/l. (v) Patients receiving mesalazine (5ASA) must have had a stable dose for at least one month. (vi) Patients receiving Azathioprine, or Mercaptopurine (who will be separately stratified) must have had a stable dose for at least 3 months (vii) Women of child bearing potential must have a negative urine pregnancy test prior to the start of study medication Exclusion Criteria (i) Patients under 18 or unable to give informed consent. (ii) Any antibiotic use within the previous 4 weeks (iii) Known sensitivity to Ciprofloxacin, Doxycycline, Hydroxychloroquine, or Budesonide (iv) Patients with a history of tendon disorders related to Fluoroquinoline administration (v) Any change to immunosuppressive therapy (Azathioprine, or Mercaptopurine) within the previous 3 months. (vi) Use of Infliximab or Adalimumab (anti-TNF antibody) or methotrexate within the previous 3 months (vii) Concurrent use of systemic corticosteroids in excess of oral prednisolone 5 mgs/day or budesonide 3mg/day) (viii) Any change to medication for Crohn's disease in previous 4 weeks. (ix) Patients with complications requiring surgery (significant intestinal obstruction, perforation or abscess) (x) CDAI >450 (xi) Participation in other trials in the last 3 months. (xii) Serious intercurrent infection or other clinically important active disease (including renal and hepatic disease) (xiii) Pregnant, post-partum (<3months) or breast feeding females (xiv) Patients with abnormal visual acuity (that does not correct with glasses) or unexplained visual symptoms (xv) Women of Child Bearing Potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period (double barrier methods such as condoms or diaphragms with spermicidal gel or foam), and for up to 4 weeks after the study. (xvi) Patients who need to continue to receive oral contraceptives (if unwilling to use double barrier methods), oral anticoagulants tricyclic antidepressants, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, Sucralfate, or Cyclosporine

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Liverpool, Merseyside, United Kingdom

Status

Recruiting

Address

Royal Liverpool and Broadgreen Unversity Hospitals Trust

Liverpool, Merseyside, L7 8XP

Site Contact

Kate Martin, SRN

kate.martin@rluhbt.nhs.uk

0151 706 4074

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. For a full description of terms please refer to our Terms, Conditions & Privacy.